C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset (Evoke/Evoke+), reflecting ongoing interest in tau-related signals within Alzheimer’s disease research.
The data were presented at the AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference during the Evoke/Evoke+ Trial Symposium, which focused on Evoke and Evoke+ cerebrospinal fluid (CSF) and plasma biomarker analyses as well as Evoke and Evoke+ exploratory subgroup analyses.
The analysis included eMTBR-tau243, the Research Use Only biomarker commercialized and measured by C2N, as part of the examination of participants enrolled in the trials.
Baseline levels of p-tau217 and eMTBR-tau243 each showed independent associations with longitudinal measures of cognitive and functional decline, and the two biomarkers provided complementary information when assessed together, according to Evoke/Evoke+ Phase 3 evaluation data.
“The inclusion of eMTBR-tau243 in Evoke/Evoke+ analyses reflects the growing interest in looking at tau biology in ways that may better predict which patients with early symptomatic Alzheimer’s disease will progress more quickly than others. This information may be instrumental for future precision medicine strategies in novel treatment development and patient care,” says Dr. Joel Braunstein, CEO and President of C2N Diagnostics.
C2N continues to advance multiple tau-related research tools, including early elements of its PrecivityTauDx™ program development, to help bring together scientific insights in both research and clinical settings in Alzheimer’s disease.
The broader Alzheimer’s research field is also seeing growing interest in the role of blood-based biomarkers in therapeutic development and clinical research. In this environment, C2N remains focused on scientific collaborations and on providing robust, analytically sound biomarker support to partners across academia, biopharma, and translational research programs.
